Robert P. Mauch

President and Chief Executive Officer at Cencora

Since October 1, 2024

Age

58 years

Education

Earned a Pharm.D. from Mercer University and a Ph.D. in pharmaceutical science from the University of South Carolina focusing on health economics and outcomes research.

Tenure

Joined COR in 2007 and progressed through multiple leadership roles including Senior VP, Group President, EVP, COO, and President before being appointed as President and Chief Executive Officer on October 1, 2024.

Also at Cencora

ESC

Elizabeth S. Campbell

Executive Vice President and Chief Legal Officer

JFC

James F. Cleary

Executive Vice President and CFO

Silvana Battaglia

Executive Vice President and Chief Human Resources Officer

About

Robert P. Mauch is a seasoned healthcare executive who has dedicated over 25 years to the growth and transformation of COR. He began his journey with the company in 2007 when COR acquired Xcenda, and over the years, he has held an array of leadership positions that have shaped his comprehensive understanding of the pharmaceutical and healthcare industries.

With a strong academic foundation, he earned advanced degrees that have contributed significantly to his strategic approach. His educational achievements include a Pharm.D. from Mercer University and a Ph.D. in pharmaceutical science from the University of South Carolina, where his focus on health economics and outcomes research has informed his leadership style.

Throughout his tenure, he has played a pivotal role in COR’s evolution, driving initiatives that have positioned the company as a global provider of pharmaceutical-centered healthcare solutions. Now serving as President and Chief Executive Officer since October 1, 2024, his career reflects a continued commitment to delivering strategic value and nurturing innovation across all levels of the organization.

$COR Performance Under Robert P. Mauch

Past Roles

Organization	Role	Date Range	Details
COR	Executive Vice President and Chief Operating Officer	October 2022 to September 2024	N/A
COR	Group President	February 2019 to September 2022	N/A
COR	Group President, Pharmaceutical Distribution & Strategic Global Sourcing	June 2017 to February 2019	N/A
AmerisourceBergen Drug Corporation	President	February 2015 to June 2017	N/A
AmerisourceBergen Drug Corporation	Senior Vice President and Chief Operating Officer	March 2014 to February 2015	N/A
AmerisourceBergen Drug Corporation	Senior Vice President, Operations	April 2012 to March 2014	N/A
AmerisourceBergen Drug Corporation	Senior Vice President of Sales and Marketing	April 2011 to April 2012	N/A
AmerisourceBergen Drug Corporation	Senior Vice President, Alternate Care Sales and Marketing	May 2010 to April 2011	N/A
Xcenda, L.L.C.	Founder	N/A	Acquired by Cencora in 2007

External Roles

Organization	Role	Date Range	Details
The Professional Society for Health Economics and Outcomes Research	Member	N/A	N/A
American Society of Managed Care Pharmacy	Member	N/A	N/A
American Pharmacists Association	Member	N/A	N/A
Covenant House of Philadelphia	Chairman of the Board	N/A	N/A

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,039,959	Annual (Fiscal 2024)	Fixed annual base salary for fiscal 2024
Employee Deferral Plan Contributions	$160,753	Fiscal 2024	Contributions made under the Deferred Compensation Plan
Company Benefit Restoration Contributions	$90,101	Fiscal 2024	Contributions to Benefit Restoration Accounts under the Deferred Compensation Plan

Performance Compensation

Data from FY 2024

Performance Share Awards

Metric Name	Details
Grant Date	November 8, 2023
Grant Date Fair Value [USD]**	$3,600,076
Target Shares	18,294 shares
Threshold Shares	9,147 shares (50% of target)
Maximum Shares	42,076 shares (230% of target, including TSR modifier)
Performance Period	October 1, 2023 to September 30, 2026
Performance Metrics & Weighting	- Compound Annual Adjusted EPS Growth Rate (75% weighting) <br> - Average Annual Adjusted ROIC (25% weighting) <br> - Relative TSR Modifier (+/- 15%, with payout capped at 100% if TSR is negative)
Vesting Schedule	Awards vest at the end of the three-year performance period, contingent on achieving the performance metrics

These performance compensation awards are designed to align the interests of executives with long-term company performance. All payouts depend on meeting the specified performance thresholds, targets, and maximum levels as detailed above.